|
1
|
Clavien PA, Petrowsky H, DeOliveira ML and
Graf R: Strategies for safer liver surgery and partial liver
transplantation. N Engl J Med. 356:1545–1559. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kucera O and Cervinkova Z: Experimental
models of non-alcoholic fatty liver disease in rats. World J
Gastroenterol. 20:8364–8376. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vernon G, Baranova A and Younossi ZM:
Systematic review: The epidemiology and natural history of
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kogure K, Ishizaki M, Nemoto M, Kuwano H
and Makuuchi M: A comparative study of the anatomy of rat and human
livers. J Hepatobiliary Pancreat Surg. 6:171–175. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clavien PA, Selzner M, Rüdiger HA, Graf R,
Kadry Z, Rousson V and Jochum W: A prospective randomized study in
100 consecutive patients undergoing major liver resection with
versus without ischemic preconditioning. Ann Surg. 238:843–850;
discussion 851–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin LM, Liu YX, Zhou L, Xie HY, Feng XW,
Li H and Zheng SS: Ischemic preconditioning attenuates
morphological and biochemical changes in hepatic
ischemia/reperfusion in rats. Pathobiology. 77:136–146. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yadav SS, Sindram D, Perry DK and Clavien
PA: Ischemic preconditioning protects the mouse liver by inhibition
of apoptosis through a caspase-dependent pathway. Hepatology.
30:1223–1231. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neuschwander-Tetri BA: Nonalcoholic
steatohepatitis and the metabolic syndrome. Am J Med Sci.
330:326–335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DuBray BJ, Gunter K, Hassan H,
Balachandran P, Upadhya GA, Knolhoff BL, Jia J, Ramachandran S,
Hotchkiss RS, Mohanakumar T, et al: Absence of BH3-only proteins
mitigates accentuation of hepatic ischemia-reperfusion injury
caused by steatosis. J Surg Res. 172:302–303. 2012. View Article : Google Scholar
|
|
10
|
Hilden M, Christoffersen P, Juhl E and
Dalgaard JB: Liver histology in a ‘normal’ population -
examinations of 503 consecutive fatal traffic casualties. Scand J
Gastroenterol. 12:593–597. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Veteläinen R, van Vliet AK and van Gulik
TM: Severe steatosis increases hepatocellular injury and impairs
liver regeneration in a rat model of partial hepatectomy. Ann Surg.
245:44–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Selzner N, Selzner M, Jochum W and Clavien
PA: Ischemic preconditioning protects the steatotic mouse liver
against reperfusion injury: An ATP dependent mechanism. J Hepatol.
39:55–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Underwood Ground KE, . Prevalence of fatty
liver in healthy male adults accidentally killed. Aviat Space
Environ Med. 55:59–61. 1984.PubMed/NCBI
|
|
14
|
Koneru B, Reddy MC, dela Torre AN, Patel
D, Ippolito T and Ferrante RJ: Studies of hepatic warm ischemia in
the obese Zucker rat. Transplantation. 59:942–946. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Centers for Disease Control and
Prevention: Overweight and obesity. http://www.cdc.gov/nccdphp/dnpa/obesity/Dec
13–2014
|
|
16
|
Berson A, De Beco V, Lettéron P, Robin MA,
Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B and
Pessayre D: Steatohepatitis-inducing drugs cause mitochondrial
dysfunction and lipid peroxidation in rat hepatocytes.
Gastroenterology. 114:764–774. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fromenty B and Pessayre D: Impaired
mitochondrial function in microvesicular steatosis. Effects of
drugs, ethanol, hormones and cytokines. J Hepatol. 26 Suppl
2:43–53. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burt AD, Mutton A and Day CP: Diagnosis
and interpretation of steatosis and steatohepatitis. Semin Diagn
Pathol. 15:246–258. 1998.PubMed/NCBI
|
|
19
|
Selzner M, Rüdiger HA, Sindram D, Madden J
and Clavien PA: Mechanisms of ischemic injury are different in the
steatotic and normal rat liver. Hepatology. 32:1280–1288. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Behrns KE, Tsiotos GG, DeSouza NF, Krishna
MK, Ludwig J and Nagorney DM: Hepatic steatosis as a potential risk
factor for major hepatic resection. J Gastrointest Surg. 2:292–298.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mokuno Y, Berthiaume F, Tompkins RG, Balis
UJ and Yarmush ML: Technique for expanding the donor liver pool:
Heat shock preconditioning in a rat fatty liver model. Liver
Transpl. 10:264–272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SW, Kang JW and Lee SM: Role of
Kupffer cells in ischemic injury in alcoholic fatty liver. J Surg
Res. 194:91–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Selzner M and Clavien PA: Resection of
liver tumors: Special emphasis on neoadjuvant and adjuvant
therapyMalignant Liver Tumors - Current and Emerging Therapies.
Clavien PA: Blackwell Science; Malden, MA: pp. 137–149. 1999
|
|
24
|
McCormack L, Petrowsky H, Jochum W, Furrer
K and Clavien PA: Hepatic steatosis is a risk factor for
postoperative complications after major hepatectomy: A matched
case-control study. Ann Surg. 245:923–930. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al-Humadi H, Theocharis S, Dontas I,
Stolakis V, Zarros A, Kyriakaki A, Al-Saigh R and Liapi C: Hepatic
injury due to combined choline-deprivation and thioacetamide
administration: An experimental approach to liver diseases. Dig Dis
Sci. 57:3168–3177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsukada K, Miyazaki T, Kato H, Masuda N,
Fukuchi M, Fukai Y, Nakajima M, Ishizaki M, Motegi M, Mogi A, et
al: Body fat accumulation and postoperative complications after
abdominal surgery. Am Surg. 70:347–351. 2004.PubMed/NCBI
|
|
27
|
Chu MJJ, Hickey AJR, Phillips ARJ and
Bartlett ASJR: The impact of hepatic steatosis on hepatic
ischemia-reperfusion injury in experimental studies: A systematic
review. BioMed Res Int. 2013:1920292013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Larter CZ and Yeh MM: Animal models of
NASH: Getting both pathology and metabolic context right. J
Gastroenterol Hepatol. 23:1635–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sikalias N, Karatzas T, Alexiou K,
Mountzalia L, Demonakou M, Kostakis ID, Zacharioudaki A, Papalois A
and Kouraklis G: Intermittent ischemic preconditioning protects
against hepatic ischemia-reperfusion injury and extensive
hepatectomy in steatotic rat liver. J Invest Surg. 23:1–12. 2017.
View Article : Google Scholar
|
|
30
|
Kanuri G and Bergheim I: In vitro and in
vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol
Sci. 14:11963–11980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schattenberg JM and Galle PR: Animal
models of non-alcoholic steatohepatitis: Of mice and man. Dig Dis.
28:247–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
London RM and George J: Pathogenesis of
NASH: Animal models. Clin Liver Dis. 11(55–74): viii2007.
|
|
33
|
Anstee QM and Day CP: The genetics of
NAFLD. Nat Rev Gastroenterol Hepatol. 10:645–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nagarajan P, Kumar Mahesh MJ, Venkatesan
R, Majundar SS and Juyal RC: Genetically modified mouse models for
the study of nonalcoholic fatty liver disease. World J
Gastroenterol. 18:1141–1153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Malínská H, Oliyarnyk O, Hubová M, Zídek
V, Landa V, Simáková M, Mlejnek P, Kazdová L, Kurtz TW and Pravenec
M: Increased liver oxidative stress and altered PUFA metabolism
precede development of non-alcoholic steatohepatitis in SREBP-1a
transgenic spontaneously hypertensive rats with genetic
predisposition to hepatic steatosis. Mol Cell Biochem. 335:119–125.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song YS, Fang CH, So BI, Park JY, Lee Y,
Shin JH, Jun DW, Kim H and Kim KS: Time course of the development
of nonalcoholic Fatty liver disease in the Otsuka long-evans
Tokushima Fatty rat. Gastroenterol Res Pract. 2013:3426482013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fukunishi S, Nishio H, Fukuda A, Takeshita
A, Hanafusa T, Higuchi K and Suzuki K: Development of fibrosis in
nonalcoholic steatosis through combination of a synthetic diet rich
in disaccharide and low-dose lipopolysaccharides in the livers of
Zucker (fa/fa) rats. J Clin Biochem Nutr. 45:322–328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang YY, Tsai TH, Huang YT, Lee TY, Chan
CC, Lee KC and Lin HC: Hepatic endothelin-1 and
endocannabinoids-dependent effects of hyperleptinemia in
nonalcoholic steatohepatitis-cirrhotic rats. Hepatology.
55:1540–1550. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ota T, Takamura T, Kurita S, Matsuzawa N,
Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, et al: Insulin
resistance accelerates a dietary rat model of nonalcoholic
steatohepatitis. Gastroenterology. 132:282–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ,
Park KH, Kim JY, Park JJ, Kim JS, Bak YT, et al: Reduced expression
of peroxisome proliferator-activated receptor-alpha may have an
important role in the development of non-alcoholic fatty liver
disease. J Gastroenterol Hepatol. 19:799–804. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Uno M, Kurita S, Misu H, Ando H, Ota T,
Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, et al:
Tranilast, an antifibrogenic agent, ameliorates a dietary rat model
of nonalcoholic steatohepatitis. Hepatology. 48:109–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fellmann L, Nascimento AR, Tibiriça E and
Bousquet P: Murine models for pharmacological studies of the
metabolic syndrome. Pharmacol Ther. 137:331–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jump DB, Tripathy S and Depner CM: Fatty
acid-regulated transcription factors in the liver. Annu Rev Nutr.
33:249–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y,
Zhang L and Wang Y: High-fat emulsion-induced rat model of
nonalcoholic steatohepatitis. Life Sci. 79:1100–1107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tschöp M and Heiman ML: Rodent obesity
models: An overview. Exp Clin Endocrinol Diabetes. 109:307–319.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Veteläinen R, van Vliet A and van Gulik
TM: Essential pathogenic and metabolic differences in steatosis
induced by choline or methione-choline deficient diets in a rat
model. J Gastroenterol Hepatol. 22:1526–1533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tahan V, Eren F, Avsar E, Yavuz D, Yuksel
M, Emekli E, Imeryuz N, Celikel C, Uzun H, Haklar G, et al:
Rosiglitazone attenuates liver inflammation in a rat model of
nonalcoholic steatohepatitis. Dig Dis Sci. 52:3465–3472. 2007.
View Article : Google Scholar : PubMed/NCBI
|
